Development and Validation of the American Heart Association’s PREVENT Equations
Circulation, ISSN: 1524-4539, Vol: 149, Issue: 6, Page: 430-449
2024
- 121Citations
- 128Usage
- 174Captures
- 15Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations121
- Citation Indexes121
- 121
- CrossRef14
- Usage128
- Abstract Views128
- Captures174
- Readers174
- 148
- 26
- Mentions15
- News Mentions15
- News15
Most Recent News
Prevention, life-saving therapies, anti-obesity meds top 2024 heart, stroke research news
American Heart Association volunteer experts issue annual list of the leading heart disease and stroke research for 2024 DALLAS, Dec. 10, 2024 — Progress in
Article Description
BACKGROUND: Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD. METHODS: The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets. RESULTS: Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763–0.809) in female and 0.757 (0.727–0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81–1.16) and 0.94 (0.81–1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD– and heart failure–specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004–0.005] and 0.005 [0.004–0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84–1.20] versus 1.39 [1.14–1.65]; P=0.01). CONCLUSIONS: PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.
Bibliographic Details
https://digitalcommons.providence.org/publications/8542; https://ecommons.aku.edu/provost_office/488; https://digitalcommons.providence.org/publications/8112; https://hsrc.himmelfarb.gwu.edu/gwhpubs/3822
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85179827775&origin=inward; http://dx.doi.org/10.1161/circulationaha.123.067626; http://www.ncbi.nlm.nih.gov/pubmed/37947085; https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067626; https://digitalcommons.providence.org/publications/8542; https://digitalcommons.providence.org/cgi/viewcontent.cgi?article=9283&context=publications; https://ecommons.aku.edu/provost_office/488; https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1488&context=provost_office; https://digitalcommons.providence.org/publications/8112; https://digitalcommons.providence.org/cgi/viewcontent.cgi?article=8859&context=publications; https://hsrc.himmelfarb.gwu.edu/gwhpubs/3822; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=4821&context=gwhpubs
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know